At 7.2% CAGR, Europe Pharmacokinetics Services Market is Projected to be Worth US$ 387.38 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031, registering a CAGR of 7.2% from 2023 to 2031. Expanding range of application of pharmacokinetic studies and outsourcing of pharmacokinetics services to CROs are among the critical factors attributed to drive the Europe pharmacokinetics services market growth.

Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.

On the contrary, limited reach of pharmacokinetics service providers in emerging countries hampers the growth of Europe pharmacokinetics services market.

Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held 50.6% market share in 2023, amassing US$ 112.37 million. It is projected to garner US$ 202.28 million by 2031 to register 7.6% CAGR during 2023-2031.

In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held 35.4% share of Europe pharmacokinetics services market in 2023, amassing US$ 78.54 million. It is anticipated to garner US$ 150.73 million by 2031 to expand at 8.5% CAGR during 2023-2031.

By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held 22.3% market share in 2023, amassing US$ 49.51 million. It is projected to garner US$ 95.67 million by 2031 to register 8.6% CAGR during 2023-2031.

By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held 43.3% market share in 2023, amassing US$ 96.18 million. It is projected to garner US$ 177.18 million by 2031 to register 7.9% CAGR during 2023-2031.

By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that France captured 22.2% share of Europe pharmacokinetics services market in 2023. It was assessed at US$ 49.21 million in 2023 and is likely to hit US$ 95.06 million by 2031, registering a CAGR of 8.6% during 2023-2031.

Key players operating in the Europe pharmacokinetics services market are Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA; among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com